A Phase 4 interventional study of N1539 in Post Operative Pain, sponsored by Baudax Bio. Terminated at 3 sites in United States. Open to participants aged 2 Years to 16 Years. Per ClinicalTrials.gov, last updated 2023-09-13.
Sponsored by Baudax Bio · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 24 studies testing meloxicam in Pain, Postoperative — 2 open to participants now, 3 under way, none of them phase 3. Meloxicam · Pain, Postoperative.
Among the 24 studies testing meloxicam in Pain, Postoperative, this one is the 23rd largest by enrollment, is one of 2 that started in 2022, is one of 5 in phase 4, and was the 20th registered.
5,654 studies on the registry are indexed under Pain, Postoperative; 1,233 are open to participants now.
Browse Pain, Postoperative studies →2 of the 24 studies testing meloxicam in Pain, Postoperative are open now, in 2 countries. Recruiting first, the newest first:
University of Oklahoma · Sites in United States
Ages 18–110
Beijing Tide Pharmaceutical Co., Ltd · Sites in China
Ages 18–70
By country, each count listing its studies:
Meloxicam: first FDA approval 2000 (MOBIC), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →
Of the 676 Pain, Postoperative studies recruiting now, 239 (35%) set no upper age limit and 327 (48%) stop at 75 or younger; 74 take children under 18; 128 take healthy volunteers.
This study: 2 Years to 16 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
24 studies; the count open now beside each. This study's row is marked.
First in 2015; this study’s year is marked. 2 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 19 is below the median of 75 across 4,835 interventional studies indexed under Pain, Postoperative.
Median enrollment 112 across the 24 interventional studies. Of the 20 that completed or were terminated, 19 (95%) have results posted.
This tab as a report to print or save as PDF → With an account.
23 of 24 have an industry lead sponsor. The 4 most frequent:
Baudax Bio is the lead sponsor of 11 studies on the registry; none are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 4 (80%) have results posted.
Baudax Bio has 9 studies filed under Pain, Postoperative — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 24 studies testing meloxicam in Pain, Postoperative, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study is an open-label, multicenter evaluation of Safety and Pharmacokinetics of N1539 in postoperative Pediatric subjects aged 2 to \<17 years.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
N1539 (Meloxicam IV) 0.6 mg/kg (maximum 30 mg) Q24H
Drug: N1539
Once daily
Also known as: Meloxicam IV
Number of Subjects Experiencing an AE
Number of study subjects who experienced an AE
Time frame: Through study completion, approximately 28 Days
| Milestone | N1539 |
|---|---|
| Started | 19 |
| Completed | 19 |
| Not completed | 0 |
Number of study subjects who experienced an AE
| Participants | N1539 |
|---|---|
| Number of Subjects Experiencing an AE | 3 |
Collected over 28 Days following study dosing. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| N1539 | 0/19 (0%) | 0/19 (0%) | 3/19 (15.8%) |
| Event | N1539 |
|---|---|
| Tooth infectionInfections and infestations | 1/19 |
| PyrexiaGeneral disorders | 1/19 |
| Oropharyngeal painRespiratory, thoracic and mediastinal disorders | 1/19 |
| NauseaGastrointestinal disorders | 1/19 |
| Age, Categorical(Participants) | N1539 |
|---|---|
| <=18 years | 19 |
| Between 18 and 65 years | 0 |
| >=65 years | 0 |
| Age, Continuous(years) | N1539 |
|---|---|
| Median | 16 (12 to 16) |
| Sex: Female, Male(Participants) | N1539 |
|---|---|
| Female | 9 |
| Male | 10 |
| Race (NIH/OMB)(Participants) | N1539 |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 2 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 2 |
| White | 15 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
| Region of Enrollment(participants) | N1539 |
|---|---|
| United States | 19 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Feb 2022 to primary completion in Jul 2022, 4 months.
Results were first posted in Sep 2023, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Aug 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Meloxicam
Baudax Bio